Looking downstream of PLCG2 in the KEGG pathway database [86], we hypothesize that a tumor with high recruitment of PLCG2 could be successfully treated with combinations of COX-, ERK-, and PKC-inhibitors. The gene discussed is PRRT2; the disease is neoplasm.